SEMAGLUTIDE - 3mg
Semaglutide is a long-acting analog of the human GLP-1 hormone, a key regulator of glucose metabolism and appetite. In laboratory studies, it is recognized for its ability to mimic endogenous GLP-1 activity, stimulating glucose-dependent insulin secretion, reducing glucagon release, delaying gastric emptying, and promoting satiety.
A synthetic glucagon-like peptide-1 (GLP-1) receptor agonist modeled for laboratory research.
Semaglutide is a long-acting analog of the human GLP-1 hormone, a key regulator of glucose metabolism and appetite. In laboratory studies, it is recognized for its ability to mimic endogenous GLP-1 activity, stimulating glucose-dependent insulin secretion, reducing glucagon release, delaying gastric emptying, and promoting satiety.
Structurally, Semaglutide is based on the native GLP-1 (7–37) peptide but modified with substitutions and a fatty acid chain attachment, allowing for binding to albumin and resistance to enzymatic degradation. These modifications extend its half-life significantly compared to native GLP-1, making it suitable for weekly dosing in experimental settings.
Titan research and immune system function
Type 2 Diabetes Research:
Investigated for its ability to improve glycemic control via enhanced insulin secretion and reduced glucagon output.
Obesity & Appetite Regulation:
Studied for its effects on hunger suppression and caloric intake reduction in experimental models.
Metabolic Syndrome:
Examined for its influence on body weight, lipid metabolism, and cardiovascular risk markers.
Neuroendocrine Interaction:
Explored in studies on GLP-1’s impact on brain regions involved in appetite and energy balance.
Cardiometabolic Outcomes:
Used in research examining long-term impacts on blood pressure, inflammation, and vascular health.
Titan research and immune system function
GLP-1 Receptor Activation:
Directly stimulates GLP-1 receptors to regulate glucose and appetite-related pathways.
Extended Half-Life Studies:
Structural modifications allow for once-weekly administration in research models.
Energy Balance Regulation:
Modulates hypothalamic centers responsible for hunger and satiety cues.
(I) Wilding, J. P. H., et al. (2021). Once-weekly Semaglutide in adults with overweight or obesity. → In the STEP 1 trial, participants experienced early and steady weight loss, with ~2.4% reduction at 4 weeks. [New England Journal of Medicine, 384(11), 989–1002]
(II) Davies, M., et al. (2015). Semaglutide as a GLP-1 receptor agonist for weight and glucose control. → Early onset of weight loss observed starting in the first 2 weeks with increasing effects by week 4. [The Lancet Diabetes & Endocrinology, 3(5), 371–381]
(III) Rubino, D., et al. (2021). Effect of Semaglutide on weight loss in adults with obesity: STEP 3 trial. → Showed cumulative dose-response effect, with initial weight reduction evident as early as week 1.
The chart illustrates the progressive weight reduction associated with semaglutide over a four-week period in human clinical data. At week 1, participants demonstrated an estimated 0.5% reduction in body weight, suggesting a modest but measurable early effect. By week 2, this reduction more than doubled to 1.2%, indicating that semaglutide’s impact becomes more pronounced with continued administration.
By week 4, the weight loss effect reached 2.5%, showing a clear upward trajectory over the study period. The pattern highlights a dose-duration relationship, where longer treatment is associated with greater reductions in body weight. Overall, the data underscores semaglutide’s efficacy in supporting sustained weight loss within a short timeframe, aligning with its clinical positioning as a potent therapy for obesity and metabolic management.
Form:
Lyophilized Powder
Storage (unreconstituted):
- Store at 2–8 °C (refrigerated), protected from light
- For long-term storage, keep at –20 °C.
- Avoid repeated freeze–thaw cycles.
Reconstitution:
- Reconstitute with sterile water for injection or 0.9% NaCl immediately prior to use. Use aseptic technique.
Storage (after reconstitution):
- Store at 2–8 °C.
- Use within 7–10 days.
- Discard any unused solution after this period.
- Handle under sterile conditions.
- Do not shake vigorously (may cause peptide denaturation).
- Inspect visually for particulate matter or discoloration before use.
Issued for quality verification of tested material.
Feedback highlighting proven outcomes and reliability.
